StreetInsider.com News Articles

Form 4 Ceribell, Inc. For: Oct 01 Filed by: Woo Raymond

Fri, 02 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261002/27143602.html

Ceribell (CBLL) PT Raised to $33 at TD Cowen

Fri, 02 Oct 2026 04:59:05 -0400

TD Cowen analyst Joshua Jennings raised the price target on Ceribell (NASDAQ: CBLL) to $33.00 (from $29.00) while maintaining a Buy rating.

The analyst comments "CBLL Has Made Considerable Progress in its First Two Years as a Public Company: In mid-September, we hosted a virtual call with Dr. Jane Chao and Scott Blumberg, CEO and CFO of CBLL. The company is nearing the two-year anniversary of its IPO. It has accomplished a lot since its public debut, including surpassing the revenue expectations we outlined in our November 2024 initiation. CBLL has beaten the Street's sales forecasts and raised its revenue guidance

Ceribell (CBLL) PT Raised to $33 at TD Cowen

Fri, 02 Oct 2026 04:59:05 -0400

TD Cowen analyst Joshua Jennings raised the price target on Ceribell (NASDAQ: CBLL) to $33.00 (from $29.00) while maintaining a Buy rating.

Form 144 Ceribell, Inc. Filed by: Woo Raymond

Thu, 01 Oct 2026 10:45:00 -0400

si-local-file:///var/storage/secattach/20261001/27133532.html

Ceribell gets FDA clearance for new EEG analysis software features

Wed, 30 Sep 2026 07:00:13 -0400

Ceribell, Inc. (Nasdaq: CBLL) announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for new software for its EEG platform, adding quantitative EEG trending and amplitude-integrated EEG analysis capabilities.

The cleared software update adds three features to the Ceribell System. The first is Alpha-Delta Ratio and Relative Alpha Trending, which provides continuous brain monitoring intended to help detect early signs of brain distress and reduced blood flow in patients with conditions such as aneurysmal subarachnoid hemorrhage. The second is Burst Suppression Monitoring, which offers real-time visualization of brain activity to assist clinicians in adjusting sedation for severe seizures

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Wed, 30 Sep 2026 07:00:00 -0400

New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indications

SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Ceribell System that makes it easier and faster for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions.¹

Brain monitoring with electroencephalography (EEG) can generate hours

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Wed, 30 Sep 2026 07:00:00 -0400

New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indications

Brain monitoring with electroencephalography (EEG) can generate hours

BTIG Reiterates Buy Rating on Ceribell (CBLL)

Mon, 21 Sep 2026 06:04:28 -0400

BTIG analyst Marie Thibault reiterated a Buy rating and $30.00 price target on Ceribell (NASDAQ: CBLL).

The analyst commented: "Last week, we hosted Ceribell CEO Jane Chao, PhD and CFO Scott Blumberg for investor meetings in NYC. The meetings included discussion of the commercial strategy, Veterans Affairs (VA) expansion, the pediatric/neonate ramp, upcoming delirium launch, pipeline updates, and the path to profitability. Management highlighted their confidence in the convergence of growth drivers heading into 2027. We came away from these conversations encouraged and believe CBLL is on track for a long runway of growth. We are positive on CBLL for its

Form 4 Ceribell, Inc. For: Sep 15 Filed by: Chao Xingjuan

Thu, 17 Sep 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260917/27077224.html

Form 4 Ceribell, Inc. For: Sep 15 Filed by: Blumberg Scott

Thu, 17 Sep 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260917/27077217.html

Form 144 Ceribell, Inc. Filed by: Blumberg Scott

Tue, 15 Sep 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260915/27065363.html

Form 144 Ceribell, Inc. Filed by: Chao Xingjuan

Tue, 15 Sep 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260915/27065228.html

BTIG Reiterates Buy Rating on Ceribell (CBLL)

Fri, 11 Sep 2026 06:15:25 -0400

BTIG analyst Marie Thibault reiterated a Buy rating and $30.00 price target on Ceribell (NASDAQ: CBLL).

The analyst commented: "Next week, we will be hosting investor meetings with Ceribell CEO Jane Chao, PhD and CFO Scott Blumberg in New York City. CBLL is the first entrant and market leader in point-of-care (POC) rapid EEG, leveraging its proprietary AI-driven Clarity algorithm, the first to receive an on-label indication for Electrographic Status Epilepticus (ESE) diagnosis. Earlier this year, the company received FDA approval for the Ceribell Delirium Monitor and positive pilot feedback has supported a pull forward of the full commercial launch to

Form 4 Ceribell, Inc. For: Sep 08 Filed by: Foehr David

Thu, 10 Sep 2026 20:27:00 -0400

si-local-file:///var/storage/secattach/20260910/27049810.html

Form 4 Ceribell, Inc. For: Sep 08 Filed by: Woo Raymond

Thu, 10 Sep 2026 20:24:00 -0400

si-local-file:///var/storage/secattach/20260910/27049805.html

Ceribell (CBLL) PT Raised to $29 at Raymond James

Thu, 03 Sep 2026 05:19:26 -0400

Raymond James analyst Jayson Bedford raised the price target on Ceribell (NASDAQ: CBLL) to $29.00 (from $24.00) while maintaining a Strong Buy rating.

The analyst comments "We roll out 2028 estimates and raise our price target to $29. A deeper dive into our model yields better appreciation for the various new drivers that should ultimately increase utilization and drive upside to consensus estimates. CBLL has a scalable model that should benefit from the stacking of new opportunities (neonates, pediatric, delirium) and has the potential to inflect utilization over the next few quarters. This dynamic, coupled with a host of new products

Ceribell (CBLL) PT Raised to $29 at Raymond James

Thu, 03 Sep 2026 05:19:26 -0400

Raymond James analyst Jayson Bedford raised the price target on Ceribell (NASDAQ: CBLL) to $29.00 (from $24.00) while maintaining a Strong Buy rating.

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Manni Joseph S.

Tue, 25 Aug 2026 19:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26976049.html

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Manni Joseph S.

Tue, 25 Aug 2026 19:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26976049.html

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Foehr David

Tue, 25 Aug 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260825/26976045.html

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Foehr David

Tue, 25 Aug 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260825/26976045.html

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Woo Raymond

Tue, 25 Aug 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260825/26976042.html

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Woo Raymond

Tue, 25 Aug 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260825/26976042.html

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Blumberg Scott

Tue, 25 Aug 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260825/26976039.html

Form 4 Ceribell, Inc. For: Aug 21 Filed by: Blumberg Scott

Tue, 25 Aug 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260825/26976039.html